1. Compugen will participate in a fireside chat at a healthcare conference. 2. The conference is on March 11, 2025, in Miami Beach, Florida. 3. Compugen is developing cancer immunotherapies with two candidates in Phase 1. 4. The company utilizes its Unigen™ platform for drug target discovery. 5. There is a potential collaboration with AstraZeneca on a bispecific antibody.
Management presence at a major healthcare conference can boost investor confidence. Previous similar events have often led to positive price movements for biotech firms.
The conference may attract investor attention, enhancing CGEN's visibility and credibility. Increased interest can lead to positive stock movement due to heightened investor engagement.
Investor sentiment may fluctuate leading up to and following the event. Positive updates could result in immediate trading volume spikes.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, Miami Beach, Florida, on Tuesday, March 11, 2025, at 8:00 AM ET.
A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: [email protected]
Tel: +1 (628) 241-0071
SOURCE Compugen Ltd.